Northwest Biotherapeutics, Inc. (NWBO) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Bethesda, MD, 미국. 현재 CEO는 Linda F. Powers.
NWBO 을(를) 보유 IPO 날짜 2001-12-14, 25 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $308.14M.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
